Context sidebar

Information

16.02.2022

Authorised complementary and herbal medicinal products

This report provides, among other things, an overview of the number of authorisations of complementary and herbal medicines with indication and complementary medicines without indication in 2021.

01.02.2022

Use of titanium dioxide in medicinal products

The pharmaceutical excipient titanium dioxide remains permissible in Switzerland until further notice

01.01.2022

Changes to the guidance document Temporary authorisation of human medicinal products HMV4

Simplification of the procedure for “ex officio" temporary authorisation

01.11.2021

New guidance document: Involvement of patient organisation in assessment of patient information HMV4

The new guidance document is valid with effect from 1 November 2021.

01.09.2021

Update to the forms New authorisation of human medicinal products HMV4 and Variations and authorisation extensions HMV4

Consent to exchange of information for applications in collaboration with Access Consortium and Project Orbis

04.08.2021

Executive Summary - Benchmarking 2021

Comparison of Swiss approval times for human medicines with the EU and the USA

01.07.2021

Modification of various documents relating to authorisation

ZL109_00_001e_WL / ZL104_00_002e_WL

02.03.2021

Modification of the form New authorisation of human medicinal products

ZL100_00_001e_FO

02.03.2021

Modification of the form Variations and extensions

ZL300_00_003e_FO

01.03.2021

Standardisation of headers and footers in Authorisation division guidance documents and forms

The adjustments are of a purely formal nature

Top of page